Compare · BDMD vs BSX
BDMD vs BSX
Side-by-side comparison of Baird Medical Investment Holdings Ltd (BDMD) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDMD and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $62.32B, about 2674.9x BDMD ($23.3M).
- Over the past year, BDMD is down 62.3% and BSX is down 54.6% - BSX leads by 7.7 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- BSX has more recent analyst coverage (25 ratings vs 0 for BDMD).
- Company
- Baird Medical Investment Holdings Ltd
- Boston Scientific Corporation
- Price
- $0.58+1.98%
- $44.38+0.50%
- Market cap
- $23.3M
- $62.32B
- 1M return
- -47.19%
- +1.88%
- 1Y return
- -62.28%
- -54.61%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 5
- 5
- Recent ratings
- 0
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BDMD
- Baird Medical Highlights Global Expansion and Strategic Progress During Third Quarter 2026
- SEC Form SCHEDULE 13G filed by Baird Medical Investment Holdings Ltd
- SEC Form 6-K filed by Baird Medical Investment Holdings Ltd
- SEC Form 6-K filed by Baird Medical Investment Holdings Ltd
- SEC Form 424B5 filed by Baird Medical Investment Holdings Ltd
- Baird Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Baird Medical Highlights Participation at CIRSE 2026 and Showcases Microwave Ablation Technology
- SEC Form 6-K filed by Baird Medical Investment Holdings Ltd
- Baird Medical Reports 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026
- Baird Medical Expands Global Microwave Ablation Footprint with Additional Product Registrations in Pakistan
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events